[Bioavailability of a delayed-action aminophylline preparation]

Area of Science:

• Pharmacokinetics
• Drug Absorption
• Theophylline Metabolism

Context:

• Aminophylline is a common bronchodilator used in respiratory conditions.
• Sustained-release formulations aim to provide consistent drug levels and reduce dosing frequency.
• Bioavailability studies are crucial for comparing different drug formulations.

Purpose:

• To compare the bioavailability and absorption characteristics of Aminomal-R (aminophylline sustained-release) tablets against an oral aminophylline solution.
• To evaluate the impact of sustained-release formulation on theophylline absorption kinetics.
• To project plasma concentration profiles for multiple dosing regimens based on single-dose data.

Summary:

• A single-dose bioavailability study found Aminomal-R tablets exhibited statistically similar bioavailability to the standard oral aminophylline solution.
• However, Aminomal-R demonstrated significantly slower absorption, indicated by longer peak plasma times (3.6 h vs 1.3 h) and lower peak plasma concentrations (16.8 mg/l vs 21.1 mg/l).
• Multiple dosing projections suggested a reduced dosage interval to concentration ratio for Aminomal-R (1.8 vs 3.1), implying altered dosing frequency requirements.

Impact:

• The findings suggest that while Aminomal-R provides equivalent overall theophylline absorption, its altered pharmacokinetic profile necessitates careful consideration for optimal dosing strategies.
• Clinicians should be aware of the slower absorption and lower peak concentrations when prescribing Aminomal-R to ensure therapeutic efficacy.
• Further studies may be warranted to establish appropriate dosing intervals for Aminomal-R in various patient populations.